| Name | Value |
|---|---|
| Revenues | 244.4K |
| Cost of Revenue | 86.2K |
| Gross Profit | 158.2K |
| Operating Expense | 4,239.4K |
| Operating I/L | -4,081.3K |
| Other Income/Expense | 84.4K |
| Interest Income | 92.4K |
| Pretax | -3,996.9K |
| Income Tax Expense | 92.4K |
| Net Income/Loss | -3,996.9K |
Femasys Inc. is a biomedical company specializing in women's healthcare solutions. The company's primary focus is on developing and commercializing a range of products for permanent birth control, artificial insemination, endocervical curettage, and uterine cancer detection testing. Their products, including FemBloc, FemChec, FemaSeed, FemCerv, and FemEMB, are targeted at obstetrics-gynecological physicians, reproductive endocrinologists, and women's healthcare provider organizations. Femasys also offers non-surgical product technologies to support their core offerings, generating revenue from sales in the United States, Europe, Canada, Japan, and other international markets.